Haffty Laboratory - Select Publications

Dr. Haffty has published work which evaluates cancer biomarkers by staining TMA (Tissue Micro Array) slides to predict responses to various therapy and clinical outcomes.

Select publications include:

Zhang C, Liu J, Huang G, Zhao Y, Yue X, Wu H, Li J, Zhu J, Shen Z, Haffty BG, Hu W, Feng Z. Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev. 2016 Sep 1;30(17):1956-70. doi: 10.1101/gad.283283.116. PMID: 27664236

Zhang C, Liu J, Zhao Y, Yue X, Zhu Y, Wang X, Wu H, Blanco F, Li S, Bhanot G, Haffty BG, Hu W, Feng Z. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. Elife. 2016 Jan 11;5:e10727. doi: 10.7554/eLife.10727. PMID: 26751560

Mehta M, Khan A, Danish S, Haffty BG, Sabaawy HE. Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition. Mol Cancer Ther. 2015 May;14(5):1171-80. doi: 10.1158/1535-7163.MCT-14-0708.

Wall BA, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S. Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells. Pigment Cell Melanoma Res. 2015 Jan;28(1):105-9. doi: 10.1111/pcmr.12327.

Wu H, Schiff DS, Lin Y, Neboori HJ, Goyal S, Feng Z, Haffty BG. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Radiat Res. 2014 Dec;182(6):618-25. doi: 10.1667/RR13856.1. PMID: 25409124

Li X, Li L, Moran MS, Jiang L, Kong X, Zhang H, Zhang X, Haffty BG, Yang Q. Prognostic significance of calcium-sensing receptor in breast cancer. Tumour Biol. 2014 Jun;35(6):5709-15. doi: 10.1007/s13277-014-1756-9. Epub 2014 Mar 1. PMID: 24584713

Li X, Yang Q, Yu H, Wu L, Zhao Y, Zhang C, Yue X, Liu Z, Wu H, Haffty BG, Feng Z, Hu W. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget. 2014 Feb 15;5(3):788-801. PMID: 24553191

Wall BA, Wangari-Talbot J, Shin SS, Schiff D, Sierra J, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S. Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res. 2014 Mar;27(2):263-74. doi: 10.1111/pcmr.12207. Epub 2014 Jan 22. PMID: 24330389

Schonewolf CA, Mehta M, Schiff D, Wu H, Haffty BG, Karantza V, Jabbour SK. Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation. World J Gastrointest Oncol. 2014 Mar 15;6(3):74-82. doi: 10.4251/wjgo.v6.i3.74.

Li Y, Moran MS, Huo Q, Yang Q, Haffty BG. Post-mastectomy radiotherapy for breast cancer patients with t1-t2 and 1-3 positive lymph nodes: a meta-analysis. PLoS One. 2013 Dec 3;8(12):e81765. doi: 10.1371/journal.pone.0081765. eCollection 2013. PMID: 24312582 [PubMed - indexed for MEDLINE]

Khan AJ, Parikh RR, Neboori HJ, Goyal S, Haffty BG, Moran MS. The relative benefits of tamoxifen in older women with T1 early-stage breast cancer treated with breast-conserving surgery and radiation therapy. Breast J. 2013 Sep-Oct;19(5):490-5. doi: 10.1111/tbj.12150. Epub 2013 Jun 26. PMID: 23800027 [PubMed - indexed for MEDLINE]

Jones T, Neboori HJ, Wu H et. al.; Are Breast Cancer Subtypes Prognostic for Nodal Involvement and Associated With Clinical-Pathologic Features at Presentation in Early-Stage Breast Cancer?; Annals of Surgical Oncology. PMID: 23661183; Published September, 2013.

Danish HH, Goyal S, Taunk NK, Wu H, Moran MS, Haffty BG. Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) as a prognostic marker for local control in T1-2 N0 breast cancer treated with breast-conserving surgery and radiation therapy (BCS + RT). Breast J. 2013 May-Jun;19(3):231-9. doi: 10.1111/tbj.12097. Epub 2013 Mar 26. PMID: 23528130 [PubMed - indexed for MEDLINE]

Li X, Xu B, Moran MS, Zhao Y, Su P, Haffty BG, Shao C, Yang Q. 53BP1 functions as a tumor suppressor in breast cancer via the inhibition of NF-κB through miR-146a. Carcinogenesis. 2012 Dec;33(12):2593-600. doi: 10.1093/carcin/bgs298. Epub 2012 Oct 1. PMID: 23027628 [PubMed - indexed for MEDLINE] Free Article

Zhu J, Li X, Kong X, Moran MS, Su P, Haffty BG, Yang Q. Testin is a tumor suppressor and prognostic marker in breast cancer. Cancer Sci. 2012 Dec;103(12):2092-101. doi: 10.1111/cas.12020. Epub 2012 Oct 22. PMID: 22957844 [PubMed - indexed for MEDLINE] Free Article

Axelrod DE, Shah K, Yang Q, Haffty BG. Prognosis for Survival of Young Women with Breast Cancer by Quantitative p53 Immunohistochemistry. Cancer Clin Oncol. 2012;1(1):52-64. PMID: 26322145

Neboori HJ, Haffty BG, Wu H et. al.; Low p53 Binding Protein 1 (53BP1) Expression is Associated with Increased Local Recurrence in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy (BCS+RT); International Journal of Radiation Oncology, Biology, Physics. PMID:22520477; Published August, 2012

Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, Haffty BG, Pantel K, Massagué J, Kang Y.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell. 2011 Dec 13;20(6):701-14. doi: 10.1016/j.ccr.2011.11.002. Epub 2011 Dec 1. PMID: 22137794

Taunk NK, Goyal S, Wu H, Moran MS, Chen S, Haffty BG. DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer. Cancer. 2012 Feb 15;118(4):888-98. doi: 10.1002/cncr.26352. Epub 2011 Jul 14. PMID: 21761397

Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, Wang Y, Billheimer D, Chakravarthy AB, Brown M, Haffty B, Xia F. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res. 2011 Aug 15;71(16):5546-57. doi: 10.1158/0008-5472.CAN-10-3423. Epub 2011 Jul 8. PMID: 21742769

Taunk NK, Haffty BG, Goyal S. Radiation recall 5 years after whole-breast irradiation for early-stage breast cancer secondary to initiation of rosuvastatin and amlodipine. J Clin Oncol. 2011 Aug 1;29(22):e661-3. doi: 10.1200/JCO.2011.35.7202. No abstract available.

Taunk NK, Haffty BG, Chen S, Khan AJ, Nelson C, Pierce D, Goyal S. Comparison of radiation-induced fatigue across 3 different radiotherapeutic methods for early stage breast cancer. Cancer. 2011 Sep 15;117(18):4116-24. doi: 10.1002/cncr.26013.

Taunk NK, Goyal S, Moran MS, Yang Q, Parikh R, Haffty BG. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol. 2010 Aug;96(2):204-8. doi: 10.1016/j.radonc.2010.03.009.

Jiang L, Ma T, Moran MS, Kong X, Li X, Haffty BG, Yang Q. Mammographic features are associated with clinicopathological characteristics in invasive breast cancer. Anticancer Res. 2011 Jun;31(6):2327-34. PMID: 21737659

Zhang N, Li X, Tao K, Jiang L, Ma T, Yan S, Yuan C, Moran MS, Liang F, Haffty BG, Yang Q. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet. 2011 Apr 1;12:48. doi: 10.1186/1471-2350-12-48. PMID: 21457555

Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res. 2011 Apr 1;17(7):1807-14. doi: 10.1158/1078-0432.CCR-10-1276. Epub 2011 Feb 15. PMID: 21325066

Moran MS, Yang Q, Goyal S, Harris L, Chung G, Haffty BG. Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1236-43. doi: 10.1016/j.ijrobp.2010.07.031. Epub 2010 Nov 17. PMID: 21093162 [PubMed - indexed for MEDLINE]

Haffty BG, Goyal S, Kulkarni D, Green C, Vazquez A, Schiff D, Moran MS, Yang Q, Ganesan S, Hirsfield KM. Evaluation of single nucleotide polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS + RT). Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):385-91. doi: 10.1016/j.ijrobp.2010.02.005. Epub 2010 Jun 18. PMID: 20646866

Patel AN, Goyal S, Wu H, Schiff D, Moran MS, Haffty BG. Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat. 2011 Apr;126(3):601-7. doi: 10.1007/s10549-010-0960-6. Epub 2010 Jun 3. PMID: 20521098

Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010 Jun;17(6):688-95. doi: 10.1038/nsmb.1831. Epub 2010 May 9. PMID: 20453858

Moran MS, Yang Q, Haffty BG. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology. Breast J. 2009 Nov-Dec;15(6):571-8. doi: 10.1111/j.1524-4741.2009.00833.x. PMID: 19995377

Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 2009 Jan 6;15(1):9-20. doi: 10.1016/j.ccr.2008.11.013. PMID: 19111877

Rewari A, Lu H, Parikh R, Yang Q, Shen Z, Haffty BG. BCCIP as a prognostic marker for radiotherapy of laryngeal cancer. Radiother Oncol. 2009 Feb;90(2):183-8. doi: 10.1016/j.radonc.2008.10.020. Epub 2008 Nov 27. PMID: 19046788

Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer. 2008 Nov 1;113(9):2565-74. doi: 10.1002/cncr.23881. PMID: 18816610

Parikh RR, Housman D, Yang Q, Toppmeyer D, Wilson LD, Haffty BG. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1056-63. doi: 10.1016/j.ijrobp.2008.02.066. PMID: 18676094

Yang Q, Moran MS, Haffty BG. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat. 2009 May;115(2):343-8. doi: 10.1007/s10549-008-0068-4. Epub 2008 May 31. PMID: 18516673

Parikh RR, Yang Q, Higgins SA, Haffty BG. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):35-42. Epub 2007 Sep 12. PMID: 17855007